A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
Purpose. Evaluate efficacy and portability of the combination of the drugs Tautax (docetaxel) with a dose of 75mg/m2 1 time per 21 days and prednisolone — 10 mg per 24 h in hormone-refractory prostate cancer (HRPC) patients. Methods. Patients with verified HRPC were included in the study. Patients without being performed orchofuniculectomy were given LHRH analogues during the entire study. The treatment scheme was: tautax 75 mg/m2 1 time per 21 days as 1,5 h infusion + prednisolone — 10 mg perdoi:10.17650/1726-9776-2008-4-2-62-67 doaj:8da6804cbbbc4630bd1b6ce297ee30d4 fatcat:tst7i36yvzdrlfi236qhrmylwe